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ReviewMonocarboxylate transporters in cancerValéry L. Payen 1,2,3, Erica Mina 4, Vincent F. Van Hée 1, Paolo E. Porporato 1,4, Pierre Sonveaux 1,*ABSTRACT
Background: Tumors are highly plastic metabolic entities composed of cancer and host cells that can adopt different metabolic phenotypes. For
energy production, cancer cells may use 4 main fuels that are shuttled in 5 different metabolic pathways. Glucose fuels glycolysis that can be
coupled to the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS) in oxidative cancer cells or to lactic fermentation in
proliferating and in hypoxic cancer cells. Lipids fuel lipolysis, glutamine fuels glutaminolysis, and lactate fuels the oxidative pathway of lactate, all
of which are coupled to the TCA cycle and OXPHOS for energy production. This review focuses on the latter metabolic pathway.
Scope of review: Lactate, which is prominently produced by glycolytic cells in tumors, was only recently recognized as a major fuel for oxidative
cancer cells and as a signaling agent. Its exchanges across membranes are gated by monocarboxylate transporters MCT1-4. This review
summarizes the current knowledge about MCT structure, regulation and functions in cancer, with a specific focus on lactate metabolism, lactate-
induced angiogenesis and MCT-dependent cancer metastasis. It also describes lactate signaling via cell surface lactate receptor GPR81.
Major conclusions: Lactate and MCTs, especially MCT1 and MCT4, are important contributors to tumor aggressiveness. Analyses of MCT-
deficient (MCTþ/- and MCT/-) animals and (MCT-mutated) humans indicate that they are druggable, with MCT1 inhibitors being in advanced
development phase and MCT4 inhibitors still in the discovery phase. Imaging lactate fluxes non-invasively using a lactate tracer for positron
emission tomography would further help to identify responders to the treatments.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Tumors are metabolic entities that comprise cancer and host cells.
Their metabolic activities depend on their access to nutrients, bio-
logical activities, and spatiotemporal localization. While most cells in
the body are oxidative and fully oxidize glucose to CO2, cells exposed to
hypoxia (i.e., a local concentration of O2 below physiological cell needs)
and proliferating cells preferentially convert glucose to lactate in pro-
cesses known as anaerobic and aerobic glycolysis, respectively. These
metabolic phenotypes are at the core of tumor biology. In solid tumors,
the glycolytic switches associated with adaptation to hypoxia and cell
proliferation operate via different mechanisms. Indeed, hypoxic
adaptation is a survival mechanism that involves hypoxia-inducible
transcription factors (HIFs), whereas metabolic adaptation to cell
proliferation involves growth factors and their effectors, such as c-Myc
and Ras, with reported overlaps [1]. Other cancer cells are oxidative.
However, at the whole tumor level, increased conversion of glucose to
lactate associated with a high glycolytic rate generates millimolar
concentrations of lactic acid that is released to the extracellular
compartment [2]. Because lactic acid is hydrophilic and a weak acid,
its transport across membranes necessitates transporters that belong
to the monocarboxylate transporter (MCT) family. Their contribution to
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Among the 14 members of the family, MCT1/SLC16A1, MCT2/
SLC16A7, MCT3/SLC16A8, and MCT4/SLC16A3 (hereafter referred to
as MCTs) convey monocarboxylate ions together with protons
(Figure 1). These passive transporters are primarily localized at the
plasma membrane where they can operate bidirectionally depending
on the concentration gradient of their substrates [3e5]. They comprise
12 transmembrane (TM) helices, intracellular N- and C-termini and a
large cytosolic loop between TM6 and TM7 [4e6]. Their structure has
not been resolved by X-ray crystallography yet but has been modeled
on the basis of the structure of E. coli glycerol-3-phosphate transporter
(GlpT) and site-directed mutagenesis experiments [4,7,8]. Human
MCT1 modeling determined that lysine 38, aspartate 302, and arginine
306 are of particular importance for substrate binding and transporter
activity [4].
While MCTs share common substrates, including pyruvate, L-lactate,
ketone bodies aceto-acetate and D-b-hydroxybutyrate, and short chain
fatty acid propionate and butyrate, they differ by their relative affinities.
MCT2/SLC16A7 is the transporter with the highest affinity for mono-
carboxylates (Km range ¼ 0.1e1.2 mM according to the substrate;
0.5e0.75 mM for lactate), followed by MCT1/SLC16A1 (Km
range ¼ 1e12.5 mM according to the substrate; 3.5e10 mM for
lactate), MCT3/SLC16A8 that has an affinity for lactate comparable toe (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium 2Pole of
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Figure 1: Main characteristics of lactate transporters MCT1-4. The cartoon depicts the predicted structure of functional MCT1 that, as a dimer, interacts with 2 CD147/basigin
ancillary proteins at the cell membrane. Like MCT2-4, MCT1 is a passive symporter that shuttles lactate together with a proton along their concentration gradients across
membranes. On the bottom is a summary of know regulators of MCT expression and stability, together with MCT affinities for lactate. þ indicates induction/stabilization; - indicates
repression/destabilization; * refers to pathways that are not yet fully characterized; # refers to indirect influence; $ refers to an unlikely still existing possibility; x refers to a situation
reported only in cancer cells. For abbreviations, see list.MCT1 (Km ¼ 5e6 mM), and MCT4/SLC16A3 that has a low affinity for
lactate (Km ¼ 22e28 mM) and pyruvate (Km ¼ 153 mM) [9,10]
(Figure 1). Although lactate is not the only substrate of MCTs, it is
the most characterized in the literature and the most abundant in vivo,
particularly in tumors where it reaches concentrations up to 40 mM
[11]. Hence, this review mainly addresses MCT-mediated lactate
transport in cancer.
2. MCT EXPRESSION
2.1. MCT expression in normal tissues
MCTs are most often described to be functionally active at the cell
membrane, but expression in organelle membranes (mitochondria
and peroxisomes) has been reported as well. For example, MCTs
have been proposed to mediate lactate uptake by mitochondria for in
situ oxidation by lactate-dehydrogenases (LDHs) and putative mito-
chondrial lactate oxidases [12e17], and lactate release by peroxi-
somes following in situ production by LDHs [18]. However, the
validity of these observations has been questioned [3], and neither a
peptidic sequence nor chaperones sending MCTs to organelles have
been identified to date.
MCTs have different patterns of expression related to different func-
tions in normal tissues. Notably, none of them are expressed by b-cells
of the islets of Langerhans in the pancreas, which prevents lactic acid-MOLECULAR METABOLISM 33 (2020) 48e66  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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would result in hypoglycemia [3].
MCT1 is ubiquitously expressed. In the gut epithelium, its localization
at both apical and basolateral membranes has been suggested to
promote the absorption of short chain fatty acids produced by the gut
microbiota [19]. MCT1 is also expressed in the heart and in red
skeletal muscle fibers that use lactate as an oxidative fuel for
mitochondrial respiration [20e22]. It mediates lactic acid influx in
the proximal convoluted tubule of the kidney and in the liver pa-
renchyma, where lactate fuels gluconeogenesis after exercise [23].
However, rather than influx, MCT1 facilitates lactic acid efflux in
glycolytic cells, including white skeletal muscle fibers, erythrocytes,
astrocytes, oligodendrocytes, hypoxic cells, and immune cells, such
as activated T-lymphocytes [4].
Compared to MCT1, MCT2 expression is restricted to specific tissues
that differ when considering different species [4e6]. In humans,
MCT2 is, e.g., expressed in the liver parenchyma where it partici-
pates in lactate-fueled gluconeogenesis (the Cori cycle) and in the
proximal convoluted tubule of the kidney for the clearance of lactic
acid [24]. In neurons, MCT2 fuels mitochondrial respiration with
lactic acid produced by astrocytes, a metabolic pathway associated
with memory [25].
MCT3 is only expressed in the retinal pigment and choroid plexus
epithelia of the eye [26]. By facilitating lactic acid exchanges betweencess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 49
Reviewthe retinal pigment epithelium and the choroid, it regulates the pH of
the subretinal space.
MCT4, which has the lowest affinity for lactate among MCTs, pri-
marily facilitates lactic acid efflux from glycolytic cells, including
exercising white skeletal muscle fibers, astrocytes, immune cells,
chondrocytes, and hypoxic cells [3,6]. It has a very low affinity for
pyruvate and a higher affinity for lactate, which ensures that pyruvate
is converted to lactate before export [10], thus promoting NADþ
regeneration by the LDH-5 reaction, which is necessary for main-
taining a high glycolytic flux.
In some tissues, MCTs facilitate lactate exchanges between lactic acid-
producing cells and lactic acid-consuming cells. It is the case for
skeletal muscles, where MCT4-expressing glycolytic white muscle
fibers provide lactate to MCT1-expressing, oxidative red muscle fibers
[27,28] and for the central nervous system, where MCT1-and MCT4-
expressing glycolytic astrocytes and oligodendrocytes provide lactate
to MCT2-expressing oxidative neurons [28e30].
2.2. MCT expression in cancers
MCT1, MCT2, and MCT4 expression has been extensively character-
ized in cancer cell lines and in multiple tumor types from patients.
Their presence and cell type localization in human cancers are dis-
played in Table 1. Upregulation of MCT1, MCT2, and MCT4 during
tumor progression from normal to tumor epithelium has also been
repeatedly observed in human samples (Table 2). In one study,
decreased MCT2 expression was reported in hepatocellular carci-
nomas compared to healthy parenchyma [31] (Table 2). Surprisingly,
MCT2 expression has often been observed in the cytosol rather than at
the plasma membrane of cancer cells in breast [32], cervix [33],
colorectal [32,34], lung [32], ovary [32], prostate [35], and soft tissue
[36] cancers. Whether such atypical localization results from impairedTable 1 e Presence of MCTs in human cancers.
Cancer type Cell type
Adrenocortical carcinoma Bulk tissue
Bladder cancer Cancer cells
Brain cancer Cancer cells in all tumor types
Cancer cells in glioblastoma
Cancer cells in diffuse astrocytoma
Breast cancer Bulk tissue
Cancer cells in basal-like breast cancer
Cancer cells in TNBC
Cancer cells in invasive ductal carcinoma
Cervix cancer Cervix cancer cells
Epithelial cells
Colorectal cancer Cancer cells in colon adenocarcinoma
Gastric cancer Bulk tissue
Cancer cells in well-differentiated cancers
Head and neck cancer Cancer cells in esophageal carcinoma
Cancer cells in oral squamous cell carcinoma
Kidney cancer Cancer cells in clear renal cell carcinoma
Liver cancer Cancer cells in hepatocellular carcinoma
Lung cancer Cancer cell in NSCLC
Lymphoma Cancer cells in B-cell lymphoma,
Cancer cells in Burkitt lymphoma
Ovary cancer Bulk tissue
Prostate cancer Bulk tissue (primary tumors)
Bulk tissue (metastasis)
Cancer cells in prostatic intraepithelial neoplasia
Skin cancers Melanoma cells
Cancer cells in squamous cell skin cancer
Soft tissue cancers Cancer cells in soft tissue sarcoma
, no expression; , mild expression; þ, high expression; þþ very high expression.
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is not yet known.
2.3. Regulation of MCT expression
2.3.1. Physiological regulation of MCT expression
Physiologically, MCTs are subject to transcriptional, post-
transcriptional, translational, and posttranslational regulations (sum-
marized in Figure 1).
At the transcriptional level, exercise upregulates MCT1/SLC16A1 and
MCT4/SLC16A3 gene expression in muscles through a putative
mechanism implicating activation of the AMP-activated protein kinase
(MAPK)-peroxisome proliferator-activated receptor g coactivator 1-a
(PGC-1a) pathway [37,38]. Conversely, AMPK activation down-
regulates MCT1/SLC16A1 and MCT4/SLC16A3 transcription in Sertoli
cells [39]. Further investigations are thus required to understand the
dual role of AMPK in different tissues. The observation that PGC-1a
promotes MCT1/SLC16A1 transcription in skeletal muscles [40] is
interesting, knowing that lactate induces both PGC-1a and MCT1
expression after binding to lactate receptor G protein-coupled receptor
81 (GPR81) in L6 cells, a rat myoblast cell line [41]. Whether or not
MCT1 induction is downstream of PGC-1a and/or AMPK has not been
characterized in these independent studies. However, it is tempting to
propose the existence of a lactate/GPR81/PGC-1a/MCT1 or of a
lactate/AMPK/PGC-1a/MCT1 signaling axis through which lactate
would induce its own metabolism in target cells, in a way similar to
what butyrate does in the colon epithelium [42].
Hypoxia has been reported to stimulate MCT4/SLC16A3 transcription
owing to the presence of hypoxia response elements (HREs) in the
promoter region of the gene, making it a direct HIF-1-target gene [43].
The hypoxic induction of MCT4 could be particularly important forMCT1 MCT2 MCT4 Ref.
   [152]
  [220,221]
þ [89,160,188,190,222]
þ

þþ þ þ [32,223e225]
þ
þ
þ
þþ  [33,150]

   [32,34,156,157,226]
þ [153,155]
þ 
 þ [151,162]
þ
  [227]
  [31]
þþ þ þ [32]
þþ  [198]
þþ 
  [182]
 þ þ [35,93]
 
  
  [96,159,228]
þ þþ
þ þ þ [36,80]
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Table 2 e Changes of MCT expression during progression from normal to
tumor epithelium in humans.
Cancer type MCT1 MCT2 MCT4 Ref.
Adrenocortical cancer þ [152]
Brain cancer þ þ [89,160,188,190,222]
Breast cancer (þ) þ [32,54,223]
Cervix cancer þ þ [33]
Colorectal cancer (þ) þ [34,157,229]
Esophageal adenocarcinoma þ þ [151]
Gastric cancer (þ) [153,155]
Hepatocellular carcinoma  þ [31]
Melanoma þ þ [96]
Oral squamous cell carcinoma þ [162]
Prostate cancer (þ) [35,93]
þ, upregulation in all reported cases; (þ), non-systematic upregulation; -,
downregulation.wound healing, where cells downstream of damaged blood vessels
must switch to a glycolytic metabolism, hence export lactic acid, to
survive [44]. However, experimental evidence of the contribution of
MCT4 to wound healing is currently lacking. Interestingly, although
their respective promoters, genes, and 30-UTR sequences do not
contain HREs, several reports clearly indicate that hypoxia is also
capable of inducing MCT1/SLC16A1 and MCT2/SLC16A7 transcription
[45e50]. Expression studies performed in cancer cells suggested the
involvement of other hypoxia-activated transcription factors, such as
HIF-2 (which enhances Myc transcriptional activity) [51e53] and nu-
clear factor-kB (NF-kB) [46].
Interestingly, the promoter sequence of MCT1/SLC16A1 also contains
consensus sequences for the binding of nuclear factor of activated T-
cells (NFAT) [3], but, to our knowledge, the significance of this potential
regulatory pathway has never been investigated. Furthermore, a single
study in cancer cells reported that the MCT1/SLC16A1 promoter can
be methylated, reducing gene expression [54].
Several studies evidenced that MCTs are under the control of miRNAs.
Accordingly, miR-29a, miR-29b, miR-124, and miR-495 target the 30-
untranslated sites in MCT1/SLC16A1 mRNA, accounting for the
repression of its expression in pancreatic b-cells [55,56]. This effect
has been confirmed for miR-29a and miR-29b in mature mouse islets
[55]. Conversely, by suppressing the expression of oligodendrocyte
differentiation inhibitors, miR-219 can enhance MCT1 expression in
oligodendrocyte precursors, which participates in their differentiation
and in the generation of the myelin sheath in mice [57]. While addi-
tional miRNAs have been found to regulate MCT1 and MCT4 expres-
sion in cancer cells, to our knowledge, none have been reported to date
to influence MCT2 and MCT3 expression.
Little is known concerning translational control of MCTs, except for
MCT2/SLC16A7 mRNA translation that is increased in the brain in
response to noradrenaline, insulin, insulin-like growth factor 1 (IGF1),
and brain-derived neurotrophic factor (BDNF) in a PI3K/Akt/mTOR-
dependent manner [58e60].
To date, no posttranslational modifications of MCTs have been
described, except for an inhibitory S-nitrosation of cysteine residues in
MCT1 [61]. However, this modification was induced pharmacologically
and did not result from an endogenous production of reactive nitrogen
species. Its relevance in physiology and physiopathology thus remains
to be investigated.
The stability of MCTs, their subcellular localization at the plasma
membrane and their functions require their physical interaction with
chaperone glycoproteins of the multifunctional immunoglobulin family.
CD147/basigin is the main chaperone of MCT1, MCT3 and MCT4MOLECULAR METABOLISM 33 (2020) 48e66  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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(Figure 1). Interactions of MCT1 with gp70 and of MCT2 with CD147
have also been observed and could be species-dependent [65]. CD147
and gp70 transmembrane and intracellular C-terminus domains
interact with MCTs TM3-6 and C-terminus domains, respectively
[7,62,65,66]. An elegant study using fluorescence resonance energy
transfer (FRET) further revealed that functionally active MCT1 forms
dimers that interact with two CD147 proteins at the cell membrane
[67]. These functional units can recruit additional proteins to form
supercomplexes. Hence, MCT1 was reported to interact with cyto-
chrome oxidase (COX) in L6 cell mitochondria [14]; MCT1 and MCT4
with carbonic anhydrases CA2 [68] and CA6 [69] that facilitate lactic
acid transport across the cell membrane independently of CA catalytic
activities; and MCT4 with b1-integrin in epithelial cells, where the
complex polarized at the basolateral membrane and in the leading
edge lamellipodia of migrating cells [70]. Additional interactions have
been described in cancer cells (see Section 2.3.2).
The stability of MCTs and their associated chaperone proteins is
interdependent, as silencing one often reduces the expression of the
other [45,71e73]. Loss of the chaperone leads to inappropriate
expression of MCTs in intracellular vesicles, indicating that CD147
and gp70 target the transporters to the plasma membrane [62,74].
In epithelial cell monolayers, CD147 was shown to ensure MCT1
polarization, whereas MCT3 and MCT4 reciprocally influenced CD147
polarity [75e77]. Of note, CD147 gene expression is induced by
hypoxia [78], which could account for hypoxia-inducible MCT1
expression. There is no report addressing the sensitivity of gp70 to
hypoxia.
Finally, the abundance of MCTs at the cell plasmamembrane depends on
their turnover and recycling rates. c-AMP signaling has been shown to
target MCT1 to autophagosomes and lysosomes in endothelial cells, thus
decreasing the pool of functional MCT1 at the plasma membrane [79].
2.3.2. Regulation of MCT expression in cancer
Human cancers often express MCTs at high level (see Tables 1 and 2).
From a transcriptional standpoint, at least nine different mechanisms
have been evidenced to date to explain this observation (summarized
in Figure 1). Hypoxia can induce MCT1/SLC16A1, MCT2/SLC16A7, and
MCT4/SLC16A3 gene expression directly via HIF-1 activation for
MCT4/SLC16A3 [43], or indirectly for the two other isoforms
[45,46,48,50,80]. Oncogenic Myc signaling can trigger MCT1/
SLC16A1 and MCT2/SLC16A7 either directly of via the loss of trans-
lation repressors miR-29a and miR-29c [52,81]. MCT1/SLC16A1 is
also a direct Wnt-target gene, coupling Wnt activation to increased
lactate export in glycolytic colon cancer cells [82]. NF-kB signaling and
loss of function of p53 can further trigger MCT1/SLC16A1 transcription
[46]. Transcription factor metastasis-associated in colon cancer 1
(MACC1) signaling was reported to induce MCT1/SLC16A1 transcrip-
tion in gastric cancer cell lines [83]. PGC-1a-estrogen-related receptor
a (ERRa) signaling supports MCT1/SLC16A1 transcription, and this
axis was repressed in exercising tumor-bearing mice [84]. Extracel-
lular acidosis can activate HIF-2 and Myc, which then stimulate MCT1/
SLC16A1 transcription [53,85]. Glutamine availability supports HIF-1
activity and MCT4/SLC16A3 expression [86]. Finally, GPR81 stimula-
tion by extracellular lactate can trigger a yet unknown signaling
cascade increasing MCT1/SLC16A1 and MCT4/SLC16A3 gene
expression in pancreatic ductal adenocarcinoma (PDAC) cell lines [87].
Conversely, decreased MCT expression can be due to hyper-
methylation of gene promoters, leading to the silencing of MCT1/
SLC16A1 in breast cancer [54] and of MCT4/SLC16A3 in colorectal
carcinoma [88].cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 51
Figure 2: Metabolic symbiosis and commensalism based on the exchange of
lactate in cancer. The cartoon depicts a tumor-feeding blood vessel delivering glucose
and oxygen to cancer cells. An oxidative cancer cell is represented close to the blood
vessel, a hypoxic cancer cells remotely, and a host cell on the bottom. From a
metabolic standpoint, the hypoxic cancer cell has no choice but to perform anaerobic
glycolysis to survive, which implies having access to high amounts of glucose.
Comparatively, the oxidative cancer cell can use several different metabolic fuels. When
nearby glycolytic cells provide lactate (usually a MCT4-dependent process), it uses
lactate as an oxidative fuel preferentially to glucose (usually a MCT1-dependent pro-
cess), which increases glucose availability for the glycolytic cancer cell. The oxidative
cancer cell can obtain additional lactate by forcing the host cell to adopt a glycolytic
metabolism. When lactate is not available or when MCTs are inhibited, the oxidative
cancer cell switches to a glucose-based metabolism, thus depriving other cells from
this important resource, which ultimately kills the hypoxic cancer cell. MCT1 and MCT4
inhibitors can, thus, destroy both the metabolic symbiosis and the commensalism
based on the exchange of lactate in cancer. For abbreviations, see list. Adapted from
reference [219].
ReviewIncreased MCT1/SLC16A1mRNA stability can be due to a loss of MCT1
translation repressor miR-124, as observed in medulloblastoma [89]
and in PDAC [82]. Loss of miR-342-3p, which normally acts down-
stream of the estrogen receptor, was further found to increase MCT1
expression in triple negative breast cancer (TNBC) cells [90]. This study
revealed that MCT1/SLC16A1 mRNA is a direct target of the miRNA. An
indirect regulation of MCT4 expression was reported for miR-1, which
acted by decreasing Smad3-HIF-1 signaling, ultimately resulting in
decreased MCT4 expression in glycolytic colorectal cancer cells [91].
Posttranslational MCT1 stabilization has been observed in nutrient
stress conditions. It involves a poorly characterized mechanism
dependent on mitochondrial reactive oxygen species (mtROS) [48].
Interestingly, glucose deprivation induces autophagy and activates
Wnt-b-catenin signaling, whereas b-catenin downregulation was
recently found to reduce MCT1 expression in hepatocarcinoma cells,
thus positively coupling autophagy to high MCT1 expression [92].
Furthermore, interactions of MCT1, MCT4, and CD147 with hyaluronan
receptor CD44 were reported in breast and prostate cancer cell lines
[93,94]. In the complex, CD44 would act as an additional chaperone for
MCT1 and MCT4, and impairment of CD44 signaling decreased the
plasma membrane expression and impaired the activity of both
transporters in breast cancer cell lines [94].
3. MCT FUNCTIONS IN CANCER
As reported in Tables 1 and 2, MCTs are widely expressed in different
tumor types, not only in cancer cells but also in stromal cells. It is
therefore not surprising that they exert multiple activities in cancer,
including in metabolic exchanges, metabolic signaling, and cancer
metastasis.
3.1. MCTs facilitate lactate exchanges in tumors
In solid tumors, lactate accumulating in the extracellular matrix has for
a long time been considered as a mere metabolic waste. However,
there is now strong evidence that this energy-rich metabolite is a
substrate for a subpopulation of oxygenated cancer cells (Figure 2).
That oxidative cancer cells expressing MCT1 are capable of taking up
lactate secreted by glycolytic cancer cells expressing MCT4 has initially
be reported in 2008 [95] and has since been confirmed in several
studies [49,96e102]. Because oxidative cancer cells preferentially use
lactate as an oxidative fuel compared to glucose, they spare glucose
that becomes more available for glycolytic cancer cells [95]. This
cooperative relationship has been coined ‘metabolic symbiosis’
[95,103]. In addition to MCTs, lactate can be transferred efficiently
from cell to cell through connexin 43 that forms intercellular channels
allowing lactate diffusion from its production to its consumption site in
a tumor syncitium [104], and stromal cells can be hijacked by oxidative
cancer cells to produce lactate [105e107]. Of note, this stromal
contribution has been found to be dispensable in a model of tongue
cancer in MCT4/SLC16A3-knockout mice [108]. Once present in the
cytosol of oxidative cancer cells, lactate is oxidized to pyruvate by LDH-
1, which implies the simultaneous reduction of NADþ in NADH þ Hþ.
Pyruvate and NADH (through the malate-aspartate shuttle) can then
fuel the TCA cycle [95,97,109]. In non-small cell lung carcinoma
(NSCLC) models, especially upon orthotopic transplantation in mice,
the contribution of lactate to the TCA cycle exceeds that of glucose
[101]. An opposite situation can be encountered in metastatic breast
cancer, where glycolytic cancer cells in the bone fuel oxidative oste-
oclast metabolism with lactate, promoting bone resorption [110].
Compared to glucose-fueled respiration, oxidative lactate metabolism
could offer at least four advantages to oxygenated cancer cells. First,52 MOLECULAR METABOLISM 33 (2020) 48e66  2019 The Authors. Published by Elsevier GmbH. Tthe yield of ATP produced per molecule of lactate consumed is up to
7.5 times higher as compared to aerobic glycolysis. Then, cancer cells
preferentially utilizing lactate spare the energy required for glycolytic
enzyme synthesis and maintenance and for the phosphorylation of
glucose and fructose-6-phosphate during glycolysis. Lactate oxidation
by LDH-1 also provides the cell with energy-rich NADH, which can fuel
the mitochondrial electron transport chain (ETC) through the malate-
aspartate shuttle [109]. Finally, the LDH-1-catalyzed reaction pro-
motes lysosome acidification and autophagic vesicle maturation [111].
In the process, LDH-1 physically interacts with vacuolar-type proton-
ATPase (V-ATPase) at the lysosome surface, which suggests that the
LDH-1 reaction aliments a pool of Hþ that feed V-ATPase in order to
acidify lysosomes. Autophagy would be of particular importance for
oxidative cancer cells, because this process is necessary for the
recycling of oxidized proteins and organelles, including mitochondria
that can be damaged by their own production of mtROS [112].
To track oxidative lactate metabolism in tumors, ()-[18F]-3-fluoro-
2-hydroxypropionate (18-Flac) was developed as a tracer of lactate
for positron emission tomography (PET) imaging [113]. Imaging
lactate uptake could be of particular interest in the context of anti-
angiogenic therapy evasion that can occur, notably, when oxidative
cancer cells establish a metabolic symbiosis with glycolytic ones, as
observed in pancreatic neuroendocrine tumors and in renal cell
carcinomas [98e100].his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Importantly, several cancer cell lines, mostly highly glycolytic cancer
cells, are not able to import and/or to oxidize lactate in normoxia
[95,97,98]. This could result from low oxidative and high glycolytic
activities and/or from inadequate MCT and LDH expression patterns,
resulting in a net outward lactate flux that opposes lactate uptake.
Moreover, because MCTs are passive transporters, a high concen-
tration of exogenous lactate can inhibit the efflux of lactate from highly
glycolytic cells. This constitutes a serious problem for anticancer im-
munity, where extracellular lactate impairs the glycolytic activity of
cytotoxic T-lymphocytes and activated monocytes, their proliferation
and their function, thus promoting immune resistance [114,115].
Of note, MCTs transport other monocarboxylates than lactate. In
particular, b-hydroxybutyrate released by adipocytes is consumed by
MCT2-expressing breast cancer cells [116]. In addition to its role as a
metabolic fuel, b-hydroxybutyrate is a HDAC inhibitor that induces the
expression of tumor promoter genes in breast cancer cells, such as
cytokine IL-1b and growth factor lipocalin 2. MCT inhibition at large
could thus interfere with the transfer of monocarboxylates different
than lactate between distinct cancer cell subpopulations and between
stromal and cancer cells.
3.2. MCTs and lactate receptor GPR81 control lactate signaling
In addition to its role as a metabolic substrate, lactate is also a
signaling molecule regulating gene expression and protein activation.
Lactate can indeed be considered a tumor-promoting metabolite that
influences angiogenesis, amino acid metabolism, histone deacetylasesFigure 3: Lactate is a signaling molecule in cancer and endothelial cells. The cartoon
glycolytic cancer cell is further away. Lactate is produced from glucose in the hypoxic/glyco
promoting pathway. Once exported (usually a MCT4-dependent process), lactate diffuse
endothelial cell. Extracellular lactate can bind to lactate receptor GPR81 in the oxidative can
enter into the cell (usually a MCT1-dependent process), where it promotes pro-angiogeni
therefore take up lactate. There, lactate triggers additional pro-angiogenic pathways.
respectively. þ refers to stimulation. For abbreviations, see list.
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tumor progression (Figure 3).
3.2.1. Lactate induces tumor angiogenesis
Lactate is a pro-angiogenic agent. In oxidative cancer cells and in
endothelial cells, lactate influx through MCT1 and its oxidation by LDH-
1 generates pyruvate, which acts as a pro-angiogenic cytosolic signal.
Comparatively, owing to an unfavorable transmembrane gradient,
highly glycolytic cancer cells are resistant to lactate influx [117]. Py-
ruvate, but not lactate itself, has been described as a pseudo-hypoxic
signal that acts on HIF prolylhydoxylases (PHDs), especially PHD2
[118,119]. In the presence of oxygen and cofactors a-ketoglutarate
and vitamin C, this family of enzymes catalyzes the hydroxylation of
HIF-1a on two proline residues, targeting this HIF-1 subunit to
proteasome-mediated degradation (see reference [44] for a review).
Thus, even in the presence of enough oxygen, PHDs can be inhibited
either by oxidants or by competitors of a-ketoglutarate. In this mo-
lecular context, pyruvate competes with a-ketoglutarate, resulting in
PHD inhibition in normoxic cancer cells [117,120,121]. Yet, some
doubts persist on the exact nature of the competition [122].
PHD inhibition by lactate-derived pyruvate exerts different effects ac-
cording to the cell type: it stabilizes HIF-1a in both oxidative cancer
cells and in endothelial cells, and subsequently activate HIF-1 and
triggers the transcription of vascular endothelial growth factor-A
(VEGF-A) in cancer cells [117] and of VEGF receptor 2 (VEGFR2) and
basic fibroblast growth factor (bFGF) in endothelial cells [121,123].depicts on endothelial cell in close proximity of an oxidative cancer cell, and a hypoxic/
lytic cancer cell, and intracellular lactate activates a NDRG3-Raf-ERK1/2 tumor growth-
s along its concentration gradient and influences the oxidative cancer cell and the
cer cell, supporting mitochondrial biogenesis, lactate transport and signaling. It can also
c signaling and glutaminolysis. Similarly, the endothelial cell expresses MCT1 and can
Plain lines and dotted lines represent well-established and presumptive cascades,
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ReviewBoth VEGF-A and bFGF are well characterized pro-angiogenic factors,
and activation of their receptors expressed by endothelial cells stim-
ulates endothelial cell proliferation and migration, leading to neovessel
formation from pre-existing blood vessels [124]. In endothelial cells,
PHDs not only tag HIF-1a for proteasomal degradation but also
negatively regulate inhibitor of kB-kinase b (IkKb) expression and
activity [125]. It follows that lactate activates IkKb, resulting in the
phosphorylation of inhibitor of kBa (IkBa) and its subsequent pro-
teasomal degradation, the nuclear translocation of NF-kB and the
transcription of pro-angiogenic factor interleukin-8 (IL-8) [120]. Of
note, together with pyruvate, NADH produced by the LDH-1 reaction is
required for NF-kB activation: in the cytosol, NADH fuels NAD(P)H
oxidases (NOXs) that start to generate ROS, contributing to activation of
IkK and/or inhibition of PHDs [120]. This signaling pathway is not
activated in oxidative cancer cells because NADH generated by the
LDH-1 reaction preferentially fuels OXPHOS rather than NOXs in these
cells [109]. Altogether, lactate produced e.g. by hypoxic cancer cells
elicits a coordinated pro-angiogenic transcriptional program that in-
duces neovessel formation in tumors [11].
N-myc downstream-regulated gene 3 (NDRG3), another PHD2 target,
has also been described as an angiogenesis regulator in tumors [126].
In normoxic conditions, NDRG3 is targeted by PHD2 to the proteasome
for degradation. However, under prolonged hypoxia, intracellular
lactate accumulation is responsible for NDRG3 activation and the
consecutive stimulation of the Raf-extracellular signal-regulated kinase
(ERK) pathway, supporting tumor growth and angiogenesis [126].
Interestingly, although NDRG3 is negatively regulated by PHD2,
intracellular lactate does not stimulate NDRG3 via PHD2 inhibition, but
primarily via direct binding to NDRG3. The relevance of NDRG3 in the
pseudo-hypoxic response to extracellular lactate is questionable,
because exposure of normoxic cancer cells to high levels of exogenous
lactate led only to limited NDRG3 stabilization and signaling when
compared to hypoxia. Consequently, whether MCTs control this
pathway is unknown.
In endothelial cells and macrophages, additional pro-angiogenic ef-
fects of lactate have been described and are linked to a decrease in
VEGF (poly)ADP-ribosylation, i.e., a NADþ-dependent posttranslational
modification that limits VEGF activity. LDH-1 and (poly)ADP-ribosyl-
transferases indeed compete for NADþ: lactate oxidation to pyruvate
decreases NADþ levels, and, thereby, VEGF (poly)ADP-ribosylation
[127e130]. If the pathway is well described, the involvement of MCTs
would be logical but has not been demonstrated to date.
Overall, by various mechanisms, cancer cell, endothelial cell, and/or
macrophage exposure to lactate was phenotypically shown to
induce endothelial cell proliferation [123,131], migration
[120,121,123,131,132], tube formation [120,121,123,133], vessel
sprouting from aortic explants [121], angiogenesis in the egg
chorioallantoic membrane [130,131] and rabbit cornea [127]
models, and tumor angiogenesis in mice [117,120,121,134].
3.2.2. Lactate stimulates amino acid metabolism
In cancer cells expressing MCT1, a second signaling activity of lactate
is linked to its positive regulation of amino acid metabolism. In these
cells, PHD inhibition by lactate-derived pyruvate not only leads to HIF-
1a but also to HIF-2a stabilization and HIF-2 activation [135]. HIF-2
was reported to enhance Myc signaling, thereby promoting gluta-
mine uptake and metabolism through enhanced expression of the
inward glutamine transporter ASCT2 and of glutamine-metabolizing
enzyme glutaminase 1 (GLS1) [135]. Moreover, lactate-induced
glutamine metabolism was shown to activate mTOR [98,136], a key
nutrient sensor and master regulator of cell growth, which e.g.54 MOLECULAR METABOLISM 33 (2020) 48e66  2019 The Authors. Published by Elsevier GmbH. Tstimulates protein synthesis. Whether lactate can simultaneously
stimulate autophagy via LDH-1 and protein synthesis via mTOR in
cancer cells is an open question.
3.2.3. Lactate inhibits histone deacetylases
Extracellular lactate inhibits HDACs, resulting in histone hyper-
acetylation, reduced chromatin compactness, and changes in gene
expression [137,138]. In particular, lactate-induced hyperacetylation
was reported to facilitate DNA repair and to promote cancer cell
resistance to chemotherapy. GPR81 silencing and MCT1 inhibition
were both shown to interfere with this process [138]. Lactate-induced
histone hyperacetylation thus links extracellular lactate to intracellular
epigenome regulation, genome stability and therapy evasion.
3.2.4. Lactate activates lactate receptor GPR81
Besides intracellular activities depending on its uptake, extracellular
lactate can bind to GPR81, a lactate-activated G-protein-coupled re-
ceptor. In a physiological context, GPR81 activation inhibits lipolysis in
adipose cells in vitro and decreases the concentration of circulating
free fatty acids in vivo [139,140]. However, to our knowledge, neither
an impact of GPR81 on cancer cell lipolysis nor a potential involvement
of GPR81 on a systemic release of fatty acid to fuel cancer cells have
been investigated to date.
GPR81 is expressed in colon, lung, hepatocellular, salivary gland,
PDAC, and breast cancer cell lines, and in PDAC and breast tumors in
patients [87,141]. In PDAC cells, GPR81 stimulation was found to
transcriptionally induce the expression of MCT1, MCT4, CD147 and
PGC-1a, thereby promoting lactate uptake and oxidative (lactate)
metabolism [87]. Accordingly, GRP81 expression promoted, whereas
its downregulation decreased, PDAC xenograft growth in mice. In
breast cancer cells, GPR81 silencing reduced ATP production, stimu-
lated apoptosis and decreased c-AMP response element binding
protein (CREB)-dependent transcription of pro-angiogenic factor
amphiregulin [141]. In agreement with the latter observation, condi-
tioned medium of GPR81-silenced breast cancer cells decreased
endothelial cell tube formation, and GPR81-silenced breast tumor
xenografts showed reduced angiogenesis and growth [142]. These
observations suggest that GPR81 stimulation by lactate supports both
lactate uptake by cancer cells and lactate-induced angiogenesis,
thus collaborating with intracellular lactate processing to sustain
tumor growth and progression through non-redundant molecular
mechanisms.
3.2.5. Lactate induces immune tolerance
In tumors, lactic acid impairs anticancer immunity by repressing T-cell
proliferation, dendritic cell (DC) maturation, and natural killer (NK) cell
activity.
Lactic acid inhibits the proliferation of cytotoxic T lymphocytes (CTLs) in
a dose-dependent manner [114]. When proliferating, activated CTLs
indeed depend on glycolysis and export lactate via MCT1 [143].
Because the activity of the transporter is driven by the concentration of
lactate and protons across the cell membrane, lactic acid accumulating
in the extracellular compartment of tumors opposes lactate efflux from
these cells, hence their proliferation [114,144,145]. Molecularly, lactic
acid was further shown to repress NFAT expression in T and NK cells
[146]. These observations could have applications in other fields than
cancer: given the importance of MCT1 for CTL proliferation in immune
responses, MCT1 inhibitors were initially developed as immunosup-
pressors to inhibit tissue graft rejection [143,145,147].
In antigen-presenting DCs, a single study reported that lactic acid can
impair DC maturation by decreasing the binding efficiency of NF-kB tohis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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DNA [148]. Immature DCs displayed an anti-inflammatory phenotype.
Conversely, lactate promoted the differentiation of peripheral blood
mononuclear cells in myeloid-derived suppressor cells (MDSCs), which
contributed to immunosuppression [149]. It also decreased NK cell
activity [146,149], and the authors showed that knocking down LDHA
expression in cancer cells resulted in a smaller tumor size, an
increased number of NK cells and a decreased number of MDSCs. A
ketogenic diet, which, to some extent, prevents intratumoral lactate
accumulation, partially recapitulated this effect [149].
3.3. MCTs promote cancer metastasis
The clinical significance of MCT expression patterns has been evalu-
ated in patient tumor samples. In humans, high MCT1 and high MCT4
expression is usually associated with poor prognosis, whereas MCT2
expression correlates with a favorable outcome (prognostic values of
MCT expression are reported in Table 3). In the same line, clinical data
showed that high MCT1 expression is associated with invasion in
colorectal carcinoma [34] and metastasis in cervix [150] and esoph-
ageal adenocarcinomas [151]; in adrenocortical [152] and gastric
[153] carcinomas, and in bladder cancer [154]; and high MCT4
expression correlated with invasion in gastric cancer [155] and
metastasis in esophageal adenocarcinoma [151], and in colorectal
carcinoma [156,157]. In metastatic lesions compared to the primary
tumor, overexpression of MCT1 was reported in NSCLC [158] and
overexpression of MCT4 in melanoma [159], although an independent
study showed no statistically significant upregulation of the expression
of the transporter [96]. These observations suggest a contribution of
MCT1 and MCT4 to the metastatic process.
That MCT1 promotes cancer cell migration and invasion has been
evidenced in vitro. Indeed, glucose deprivation, a situation occurring in
tumors [2], posttranslationally induced MCT1 and CD147 expression at
the plasma membrane of human cervix carcinoma cells in a mtROS-
dependent manner, which stimulated cancer cell migration towards
glucose [48]. Other studies confirmed MCT1-induced migration and
invasion in breast and lung carcinoma, glioblastoma, and osteosar-
coma cell lines [49,50,71,73,80,160,161]. The amplitude of the effect
varied with the expression pattern of MCTs and the relative reliance of
cancer cells on glycolysis.
Mechanistically, Zhao et al. [80] proposed decreased NF-kB signaling
as a molecular mechanism coupling MCT1 repression to decreased
osteosarcoma cell migration. This has been recently confirmed inTable 3 e Prognostic value of MCT expression in human cancers.
Cancer type High MCT1 High MCT2 High MCT4 Ref.
Adrenocortical carcinoma good [152]
Bladder cancer poor Uncertain [154,220,221]
Breast cancer poor poor [196,223e225]
Clear renal cell cancer poor poor [227,230]
Colorectal cancer poor [231]
Glioblastoma poor [203]
Head and neck cancer poor [162,232]
Hepatocellular
carcinoma
good poor [31]
Lung cancer poor [193,196]
Melanoma poor poor [96,159]
Neuroblastoma poor [188]
Osteosarcoma poor [80]
Ovarian Cancer poor poor [182]
Prostate cancer poor [35,93]
Soft tissue sarcoma poor poor [36]
Testicular germ cell
cancer
poor poor [164]
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promigratory activity of MCT1 was shown to be independent of its
transporter activity, as MCT1 silencing, but not its pharmacological
inhibition, repressed cancer cell migration. Moreover, knock-in ex-
periments with a transporter-deficient version of human MCT1 in
MCT1-deficient mouse cancer cells was sufficient to restore migration.
While MCT1 silencing inhibited NF-kB signaling as well as cancer cell
migration and metastatic dissemination from primary breast cancer
in vivo, restoring its expression simultaneously restored NF-kB-
dependent cancer cell migration. MCT1 could thus directly or indirectly
interact with upstream components of the NF-kB signaling pathway,
supporting its activity. Of note, MCT1 activity in stromal cells might also
contribute to metastasis: blocking lactate influx in endothelial cells
[120,121,123] and in osteoclasts [110] impaired tumor-induced
angiogenesis and bone resorption, respectively.
Similar to MCT1, MCT4 knockdown impaired the migration and inva-
sion of various cell lines [70,71,74,162,163], with the exception of
JEG-3 testicular germ cell cancer cells on which, surprisingly, it had
the opposite effect [164]. MCT4 silencing led to abnormal CD147
trafficking and accumulation in lysosomes [74], increased focal
adhesion size [70], upregulated epithelial markers, and downregulated
mesenchymal markers [162]. MCT4, but not MCT1, directly interacts
with b1-integrin at the lamellipodium of migrating cells [70]. Because
integrin conformation is pH-sensitive [165], loss of MCT4 activity could
locally modify the transmembrane pH gradient and modify integrin
signaling and cell adhesion. This hypothesis does not rule out that the
physical interaction between MCT4 and b1-integrin could per se
regulate b1-integrin-mediated adhesion and cancer cell migration. A
selective MCT4 inhibitor would allow to discriminate between both
hypotheses by evaluating whether the activity of the transporter is
dispensable or not.
Importantly, CD147, the chaperone protein shared by MCT1 and MCT4,
is well known to trigger cancer cell migration, invasion, and metas-
tasis, notably through activation of matrix metalloproteinases (MMPs)
(see reference [166] for a recent review). Because MCT1 and CD147
on the one hand and MCT4 and CD147 on the other hand mutually
stabilize their expression at the cell plasma membrane [45,71e73],
silencing MCT1 or MCT4 might impair CD147 expression and function.
This could explain, at least in part, how MCT1 and MCT4 can promote
cancer cell migration and invasion independently of their transport
activities. Because CD44 signaling stimulates breast cancer cell in-
vasion [167], the hypothesis of a similar relationship between CD44
and MCTs is attractive, but has, to our knowledge, never been tested.
4. THERAPEUTIC MCT INHIBITION
4.1. MCT inhibitors
Several compounds non-specifically inhibit MCTs (Table 4). Among
known modes of actions, 40-diisothiocyano-2,20-stilbenedisulphonate
(DIDS) irreversibly binds to a lysine residue on MCT1 and MCT2, thus
inactivating the transporters, but not on MCT4 [8]; and organomer-
curial compounds such as p-chloromercuribenzenesulphonate (p-
CMBS) disrupt MCT-CD147 interactions, thus interfering with MCT1,
MCT3, and MCT4 expression and activity, but not with MCT2 [64].
These compounds do not present a high clinical hope for disrupting
MCT functions in cancer.
Pharmacological interest for MCT1 inhibitors rose in 2007 with the
identification of MCT1 as the target of a new class of immunomodu-
latory drugs [145]. These compounds and optimized compounds AR-
C155858 and AZD3965 were shown to inhibit lactic acid efflux from
activated T-lymphocytes [145,168]. They reduce the glycolytic rate ofcess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 55
Table 4 e MCT inhibitors.
Inhibitor MCT1
Ki (mM)
MCT2
Ki (mM)
MCT4
Ki (mM)
Other targets
Non-selective MCT inhibitors
Phloretin 5 14 41 Glucose
transporters
Quercetin 10 5 40 ERb
DIDS 434 ND NI Bicarbonate
transporters
Simvastatin >200 ND >200 HMG-CoA
reductase
p-CMBS 25 NI 25 Anion
transporters
Lonidamine 36 36 40 Mitochondrial
hexokinase
CHC 166 24 991 Mitochondrial
pyruvate carrier
Selective MCT inhibitors
AR-C155858 0.002 <0.01a NI -
AZD3965 0.002 0.02 NI -
BAY-8002 Nanomolar
range
Nanomolar
range
NI -
a In rat when associated to CD147. Abbreviations: CHC, a-cyano-4-
hydroxycinnamate; DIDS, 4,40-diisothiocyano-2,20-stilbenedisulphonate; p-CMBS, p-
chloromercuribenzenesulphonate; ND, not determined; NI, no inhibition. Data from
references [6,172,173,233e236].
Reviewthese cells and acidify their cytosol, ultimately blocking their prolifer-
ation and preventing acute rejection following organ transplantation in
mice. Lactic acid accumulation in the tumor microenvironment has
been proposed to mediate immune evasion through a similar mech-
anism of inhibition of lactate secretion [114,146]. AR-C155858 and
AZD3965 inhibit both MCT1 and MCT2, although AZD3965 is 6 times
more selective for MCT1 than for MCT2 (see Table 4). AR-C155858
directly binds to TM7-10 of MCT1, but not to MCT2 unless when
MCT2 undergoes a conformational change induced by its interaction
with CD147 [65,169e171]. Because MCT2 preferentially interacts
with gp70, both inhibitors could thus reasonably be considered as
selective MCT1 inhibitors, and no off-target effects except those
involving MCT2 have been reported to date. AR-C155858 and
AZD3965 do not inhibit MCT4, even at high doses [169e172]. Simi-
larly, MCT3-mediated lactate transport was not inhibited by a 1 h
treatment of rat pancreatic cells with 10 mM of AZD3965 [172].
Recently, BAY-8002 was reported as a novel selective MCT1 inhibitor,
with a 6-fold selectivity for MCT1 compared to MCT2, no activity on
MCT4 and no off-target effects [173]. Competition studies using
radiolabeled compounds indicated that BAY-8002 and AZD3965 acted
in a similar way, as they displaced each other. An alternative strategy
to specifically target a given MCT isoform consists in the delivery of
small interfering RNAs loaded in PEGylated chitosan nanoparticles, as
documented for MCT1 [174].
4.2. Targeting MCT-mediated lactic acid influx by cancer cells
The metabolic symbiosis based on the exchange of lactate is of
particular importance for cancer cell adaptation to glucose depletion
[95] and for tumor resistance to anti-angiogenic therapies [98e100].
When MCT1 gates lactate uptake by oxidative cancer cells, MCT1
targeting can result in lactate influx impairment, a metabolic switch
from lactate-fueled OXPHOS to aerobic glycolysis in these cells, and
the indirect death of hypoxic cancer cells consecutive to glucose
deprivation [95]. In particular, the use of small interfering RNAs vali-
dated the key role exerted by MCT1 in such symbiont. In murine
models of cancer, daily administration of MCT inhibitor a-cyano-4-56 MOLECULAR METABOLISM 33 (2020) 48e66  2019 The Authors. Published by Elsevier GmbH. Thydroxycinnamate (CHC) resulted in decreased tumor growth, an
increased tumor necrotic core associated with the eradication of
hypoxic tumor areas, and a higher sensitivity of the remaining
oxygenated tumor rim to radiotherapy [95]. The antitumor selectivity of
the approach relies on the metabolic interdependency of oxidative and
glycolytic cancer cells in a same tumor: while oxidative cancer cells
adapt to MCT1 inhibition by switching to alternative substrates (as
would also do other oxidative cells in the body), glycolytic cancer cells
depending on the symbiosis for survival cannot.
MCT1 inhibition can also interfere with oxidative cancer cells hijacking
stromal cells to get additional lactate (see Section 3.1). While in normal
conditions the co-culture of cancer-associated fibroblasts (CAFs)
would fuel cancer cell proliferation, the administration of CHC or a
MCT1 knockdown was sufficient to disrupt this relationship; thus
impairing cancer cell proliferation [107,175]. Similarly, MCT1 inhibition
or knockdown delayed the growth of mixed cancer cell-CAF xenografts
in mice. Interestingly, other studies reported MCT1 expression and the
presence of markers of an oxidative metabolism in CAFs, and the
expression of markers of a glycolytic metabolism in cancer cells [176e
178]. These features may reflect metabolic heterogeneity in cancer.
Acid clearance by CAFs was reported in an independent study [179]
and might be beneficial for cancer cells.
MCT1-mediated lactate uptake is also a characteristic of angiogenic
endothelial cells (see Section 3.2.1). Consequently, MCT1 targeting in
endothelial and cancer cells, using a silencing approach or CHC
administration, impaired lactate-induced angiogenesis in vitro and in
murine models of cancer in vivo [117,120,121]. Intriguingly, in the only
study to our knowledge where angiogenesis was assessed upon
AZD3965 treatment, the drug had no effect on small cell lung carci-
noma xenograft vascularization [180].
In the context of combination therapy, MCT1 was identified as a main
transporter facilitating the uptake of anticancer agent 3-bromopyruvate
by cancer cells [181]. A potential interference between MCT1 inhibitors
and 3-bromopyruvate should thus be addressed in future studies. The
evaluation of combination treatments should further take into account
the potential involvement of MCT1 in multidrug resistance [93,182]
and the observation that MCTs can transport additional exogenous
molecules [183].
4.3. Targeting MCT-mediated lactic acid efflux by cancer cells
MCTs facilitate lactic acid efflux from glycolytic cancer cells and
are, therefore, important pH regulators [184,185]. It is tempting to
inhibit this function in order to acidify the cytosol of glycolytic
cancer cells, inducing their death. To achieve that aim, dozens of
studies used non-specific MCT inhibitors, selective MCT1 inhibitors
and genetic approaches targeting MCT1 and/or MCT4
[45,49,50,52,72,73,101,160,162,172,180,186e198]. Impairment
of MCT-mediated efflux generally resulted in decreased pyruvic
and/or lactic acid release from glycolytic cancer cells, increased
intracellular pyruvic and/or lactic acid content resulting in cytosol
acidification, inhibition of glycolysis and an increased dependence
of the cells on mitochondrial oxidative metabolism sometimes
associated with increased oxidative stress and a drop in ATP levels
[6,11]. These effects were found to be exacerbated by hypoxia,
when cancer cells mainly relied on glycolysis, produced important
amounts of lactic acid, and expressed high MCT levels
[45,49,50,180]. In several studies, targeting CD147 recapitulated
the metabolic effects of MCT impairment [45,72,199e201].
Interestingly, in cases when MCT1 inhibition increased oxidative
mitochondrial metabolism, cancer cells generally became more
sensitive to ETC Complex I inhibitors metformin, phenformin andhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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BAY87-2243 [52,72,196e198,202] and to GLS1 inhibitor bis-2-(5-
phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) [172].
Synthetic lethality is possible, as exemplified by the combination of a
dual MCT1 and MCT4 inhibitor with metformin, which depleted
cancer cells of NADþ [202]. Moreover, additive or synergetic effects
were observed upon MCT1, MCT2, or MCT4 inhibition in combination
with chemotherapy [80,83,155,172,192,194] and radiotherapy
[155,180,189]. They could be attributed to decreased extracellular
acidity, decreased intracellular pH, and/or increased oxidative stress.
Importantly, inhibition of lactic acid secretion is the main incentive for
the current evaluation of AZD3965 in phase I/II clinical trial for Burkitt
and large B cell lymphoma, and gastric and prostate cancers (Clin-
icalTrials.gov NCT01791595).
Using AR-C155858 and AZD3965 or knockdown/knockout of selected
MCT isoforms, compensatory mechanisms were identified, including
upregulation of other MCT isoforms. In particular, upregulation of
MCT4 expression decreased the sensitivity of cancer cells to AR-
C155858, AZD3965 and to a short hairpin RNA targeting MCT1
[45,71,72,180,193]. This resistance mechanism may result from
alleviation of a competition between both transporters for CD147, and
could be reciprocal [45,72].
MCT4 expression has been associated with the tumorigenic potential
of glioblastoma cells: glioblastoma cells expressing stemness marker
CD133 expressed MCT4 at high levels, and a knockdown of MCT4
decreased CD133 expression, the ability of the cells to form neuro-
spheres and xenograft growth in mice [203]. Interestingly, lactate
transport was not influenced by MCT4 knockdown in this model. A
thorough characterization of MCT expression in tumor-initiating cells
could thus potentially lead to the identification of new therapeutic
approaches.
4.4. Targeting MCT-dependent metastasis
Quercetin, lonidamine, DIDS, and simvastatin can reduce cancer
cell migration and invasion [71]. However, due to their multiple
molecular targets, linking these results and those obtained with
CHC [48,80] to MCTs is not straightforward. To our knowledge, only
three studies were performed with AR-C155858 and AZD3965 in
this context, and showed a very limited reduction [163] or a total
absence [161,204] of effects on cancer cell migration and invasion,
despite evidence of inhibition of lactic acid transport. Because
MCT1 knockdown, but not its pharmacological inhibition, impaired
cancer cell migration and invasion, it was concluded that the ac-
tivity of the transporter is not necessary for its pro-metastatic
functions [161,204]. In breast and prostate cancer cells, MCT1
silencing, but not its pharmacological inhibition, decreased the
phosphorylation of hepatic growth factor (HGF) receptor c-Met [204]
and NF-kB activity [161], thereby decreasing cancer cell migration.
Hence, it is probable that selective MCT1 inhibitors would have
limited direct antimetastatic effects.
4.5. Potential toxicities of MCT inhibitors: learning from MCT-
deficient mice and patients
The important roles exerted by MCTs in physiology call for attention on
possible toxicities associated with MCT inhibitors. Mouse models have
been engineered for MCT1, MCT2, and MCT3 deficiency, and patients
with heterozygous missense mutations of the MCT1/SLC16A1 gene
have been reported.
In genetically engineered mouse models, a full knockout of MCT1/
SLC16A1 was found to be embryonically lethal due to neuronal defects
[205]. Comparatively, a systemic MCT1/SLC16A1þ/ genotype and an
oligodendrocyte-selective MCT1/SLC16A1 knockdown produced livingMOLECULAR METABOLISM 33 (2020) 48e66  2019 The Authors. Published by Elsevier GmbH. This is an open ac
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axon damage and decreased neuron survival in the central nervous
system [206]. The regeneration of motor and sensory peripheral nerves
after a lesion was also delayed in MCT1/SLC16A1þ/ mice. These
results are consistent with the decreased expression of MCT1
observed in neurodegenerative human diseases, such as amyotrophic
lateral sclerosis (ALS) [205,207] and Alzheimer’s disease [208], sug-
gesting an important role of this transporter in the maintenance of axon
integrity, putatively because it facilitates lactate shuttles between oli-
godendrocytes and neurons [30,205]. In another study, MCT1/
SLC16A1þ/ mice showed increased resistance to high fat diet-
induced obesity, higher insulin and leptin secretion, as well as
decreased food intake, fat absorption, fat mass, and liver steatosis
[209]. For what concerns pharmacological treatments, chronic
administration of CHC (4.7 mg daily) impaired hind limb reperfusion
following femoral artery and vein ligation in mice [134]. This effect was
attributed to an interference with lactate-induced angiogenesis, but a
specific MCT1 inhibitor would be required for further validation.
In the brain, MCT2 is preferentially expressed in neurons where it
conveys lactate uptake [6]. Adult rats injected with antisense oligo-
nucleotides in the hippocampus showed memory defects. MCT2-
deficiency did not alter short-term memory but significantly dis-
rupted long-term memory [25]. Neither glucose nor lactate rescued
amnesia, indicating that yet unknown processes dependent on MCT2
are essential for long-term memory. Accordingly, MCT2 expression
was found to be decreased in animal models of Alzheimer’s disease
[208,210].
In eyes, MCT3 facilitates lactate export by the retina. It is therefore not
surprising that MCT3/SLC16A8-knockout mice developed visual de-
fects [211]. They were attributed to a decrease in photoreceptor
currents in response to light and associated to a 4-fold increase in
lactate levels in the retina and, possibly, acidification of the subretinal
space. However, histological features of the eyes were preserved.
MCT4/SLC16A3-knockout mice have been generated in 2018 and are
viable [108]. However, a detailed analysis of phenotypic changes and
possible compensation of the deficiency by other MCT isoforms has not
yet been performed.
In humans, genetic polymorphisms of MCT1/SLC16A1 impact the
oxidative clearance of lactate by slow-twitching muscle fibers, with
carriers of 1470T>A, 2917(1414)C>T, and IVS3-17A>C variants
showing poorer lactate clearance during high intensity exercise
[212e214]. In the same line, a single case report concluded that
lactate transport deficiency caused lactate accumulation in the
exercising muscle, which was potentially responsible for episodes of
rhabdomyolysis and myoglobinuria [215]. However, the patient was
not genotyped. In 3 additional patients with “cryptic exercise intol-
erance,” heterozygous missense mutations of the MCT1/SLC16A1
gene have been reported to cause muscle and chest pain after
prolonged exercise [216], but, surprisingly, one of these mutations
did not impair MCT1 function in Xenopus oocytes [3]. Assuming that
cryptic exercise intolerance symptoms result from an impairment of
MCT1 functions, they could be caused by impaired lactic acid efflux
in skeletal muscles and/or impaired lactic acid clearance by various
tissues. More recently, novel MCT1 mutations (either homozygous or
heterozygous) have been identified in 9 patients [217]. They resulted
in recurrent and severe episodes of keto-acidosis, i.e., accumulation
of ketone bodies in the blood due to an imbalance between their
production in the liver and their use in peripheral tissues, possibly
resulting from a decreased uptake capacity of ketone bodies by
MCT1-deficient cells. Thus, keto-acidosis is important to consider
upon therapeutic MCT1 inhibition as well. To our knowledge, nocess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 57
Reviewpolymorphisms and no missense mutations have been found for
MCT2, MCT3 and MCT4 in patients. MCT4 polymorphism has been
reported in horses, but it was silent [218].
5. CONCLUSIVE REMARKS
Whereas glycolysis coupled to lactic fermentation has been reported as
the preferential metabolic mode adopted by hypoxic and proliferating
cancer and host cells, tumors also contain cells relying on an oxidative
metabolism. Like other oxidative cells in the body, oxidative cancer
cells may use several metabolic substrates, of which the main ones are
glucose, lipids, glutamine, and lactate. What distinguishes tumors from
normal tissues is that they accumulate lactate owing to a high
glycolytic activity in some tumor areas and inefficient clearance by the
abnormal tumor vasculature in general. Lactate levels in cancer may
reach 40 mM with an average concentration in human tumors of about
10 mM [2,11]. Therefore, this metabolic resource is of particular
importance for tumor growth and development. Importantly, the export
of lactate by glycolytic cells and its import by oxidative cells are gated
by MCTs.
In this review, we summarized the current knowledge about the
regulation of MCT expression, their functions in cancer, and their
druggability. We emphasized that they are expressed not only in cancer
cells but also in host cells, where they exert multiple pro-tumoral
activities. Via MCTs, lactate sustains metabolic cooperation and
commensalism (Figure 2), as well as metabolic and pro-angiogenic
signaling (Figure 3). MCTs, especially MCT1, can further promote
cancer metastasis independently of their transport activities. As such,
high MCT expression is generally correlated with poor prognosis for
cancer patients (Table 3). However, lactate may also exert part of its
pro-tumoral activity independently of MCTs, notably by binding to the
GPR81 receptor at the cell surface [87]. This information is included in
our review, because it has not been covered previously. For therapy, it
is therefore important to consider MCTs as well as other potential
therapeutic targets.
Based on their functions in cancer and analyzes of the phenotypes of
MCT-deficient mouse models and patients, we believe that MCTs,
especially MCT1 and MCT4 and also probably MCT2, have good
chances to be confirmed as potent anticancer targets for patient
treatment. A first MCT1 inhibitor, AZD3965, is currently undergoing
clinical trials for several types of cancer (ClinicalTrials.gov
NCT01791595). While we sincerely hope that this compound will exert
appreciable anticancer effects, one has to realize that anti-MCT drug
development is still in its infancy, calling for refined drug development.
In our opinion, a key parameter to solve and about which the literature
is largely silent is to reach full selectivity for a given MCT isoform. As
can be noticed in Table 4, MCT3 has been poorly studied, and the
selectivity of existing compounds preferentially targeting MCT1 versus
MCT2 is based on an unlikely, yet possible, change of MCT2 confor-
mation when binding to either gp70 of CD147. Selective MCT4 in-
hibitors have not been disclosed in the scientific literature yet, and little
is known about the role of other MCT substrates than lactate, including
pyruvate, ketone bodies and exogenous drugs, on tumor progression.
Conclusively, the last 10 years have witnessed an impressive increase
in the scientific knowledge about lactate and MCTs in cancer. MCTs
are promising anticancer targets. However, several grey zones and
black boxes are still present, that range from the (epi)genetic control of
cancer and host cells by lactate in tumors to the potential contribution
of MCTs to cancer growth at the systemic level (for example, the Cori
cycle of lactate-fueled gluconeogenesis in the liver [23]) and the
contribution of other substrates than lactate.58 MOLECULAR METABOLISM 33 (2020) 48e66  2019 The Authors. Published by Elsevier GmbH. TAUTHOR’S CONTRIBITIONS
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ABBREVIATIONS
18-FLAC ()-[18F]-3-fluoro-2-hydroxypropionate
ALS Amyotrophic lateral sclerosis
AMPK AMP-activated protein kinase
BDNF Brain-derived neurotrophic factor
bFGF Basic fibroblast growth factor
BPTES Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide
CAF Cancer-associated fibroblast
CHC a-cyano-4-hydroxycinnamate
COX Cytochrome oxidase
CREB c-AMP response element binding protein
CTL Cytotoxic T lymphocyte
DC Dendritic cell
DIDS 40-diisothiocyano-2,20-stilbenedisulphonate
EGFR Epithelial growth factor
ERK Extracellular signal-regulated kinase
ERRa Estrogen-related receptor a
ETC Electron transport chain
FRET Fluorescence resonance energy transfer
GlpT Glycerol-3-phosphate transporter
GLS1 Glutaminase 1
GLUT Glucose transporter
GPR82 G protein-coupled receptor 81
HDAC Histone deacetylase
HGF Hepatic growth factor
HIF Hypoxia-inducible transcription factor
HRE Hypoxia response element
IGF1 Insulin-like growth factor 1
IkBa Inhibitor of kBa
IkKb Inhibitor of kB-kinase b
IL Interleukin
LDH Lactate dehydrogenase
MACC1 Metastasis-associated in colon cancer 1his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MCT Monocarboxylate transporter
MDSC Myeloid-derived suppressor cell
MMP Matrix metalloproteinase
mTOR Mammalian target of rapamycin
mtROS Mitochondrial reactive oxygen species
miR MicroRNA
NDRG3 N-myc downstream-regulated gene 3
NF-kB Nuclear factor-kB
NFAT nuclear factor of activated T-cells
NK Natural killer
NOX NAD(P)H oxidase
NSCLC Non-small cell lung carcinoma
OXPHOS Oxidative phosphorylation
p-CMBS p-chloromercuribenzenesulphonate
PDAC Pancreatic ductal adenocarcinoma
PET Positron-emission tomography
PGC-1a Peroxisome proliferator-activated receptor g coactivator 1-a
PHD (HIF) prolylhydoxylase
ROS Reactive oxygen species
SLC16A Solute carrier 16A
SMCT Sodium-dependent monocarboxylate transporter
TCA Tricarboxylic acid (cycle)
TM Transmembrane
TNBC Triple negative breast cancer
V-ATPase Vacuolar-type proton-ATPase
VEGF Vascular endothelial growth factor
VEGFR2 Vascular endothelial growth factor receptor 2
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